Products 0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005%
0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005% Phase 1 Completed 💤 Quiet Glaucoma, Open-angle, Ocular Hypertension
Oct 10, 2017 → Dec 21, 2017
About 0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005% 0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005% is a phase 1 stage product being developed by Roche for Glaucoma, Open-angle. The current trial status is completed. This product is registered under clinical trial identifier NCT03293992. Target conditions include Glaucoma, Open-angle, Ocular Hypertension.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03293992 Phase 1 Completed Oct 10, 2017 Dec 21, 2017 Glaucoma, Open-angle
Product Company Stage Hype Score Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Mankind Pharma Phase 3 Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Eybelis ophthalmic solution 0.002% Santen Pharmaceutical Approved STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 Latanoprost + tafluprost Santen Pharmaceutical Pre-clinical DE-117B Eye Drops + Latanoprost Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution + Timolol ophthalmic solution 0.5% + Placebo ophthalmic solution Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 DE-117 + Latanoprost ophthalmic solution Santen Pharmaceutical Phase 3 DE-117 ophthalmic solution + Timolol ophthalmic solution Santen Pharmaceutical Phase 3 A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL Santen Pharmaceutical Phase 3 Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 2/3
Other Products from Roche